Compare ADMA Biologics Inc (ADMA) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Verizon Communications Inc — how do they compare? ADMA Biologics Inc trades at $9.52 (market cap $2.19B), while Verizon Communications Inc trades at $47.57 (market cap $195.19B). The key difference: Verizon Communications Inc is far larger — about 89.1× ADMA Biologics Inc's market cap, and Verizon Communications Inc pays a 6.02% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | VZ | |
|---|---|---|
Market Cap | $2.19B | $195.19B |
Sector | Health | Media |
52-Week High | $20.38 | $51.38 |
52-Week Low | $7.60 | $38.40 |
Enterprise Value | $2.26B | $381.90B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
Verizon (VZ) trades at $46.93, down slightly by 0.21% on the day, with a bullish technical signal from moving averages. The company shows stable fundamentals with $138.19B in 2025 revenue and consistent earnings beats in recent quarters. Recent news highlights network expansion initiatives and strategic partnerships, including a fiber deal with Alphabet. Cash flow improved significantly in 2025 with $14.86B net cash flow, though debt levels remain elevated at $121.38B long-term.
VZ presents a value opportunity with a P/E of 12.31 below sector average and strong dividend yield. Analyst consensus targets $49.69 with 36.7% buy ratings, though competition from SpaceX's Starlink and high debt pose risks. The stock's current price near support at $47 suggests limited downside if technical levels hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
